Evaluation of the effect of curcumin in improving patients with covid -19

Investigating the effect of curcumin-piperine supplementation in accelerating the recovery period of patients with covid-19

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200514047445N1

Enrollment

Registered

2020-08-10

Start date

2020-08-05

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. virus not identified

Interventions

Intervention 1: Intervention group: patients are given 3 curcumin capsules(500mg) daily after three meals. Intervention 2: Control group: Take 3 placebo (500 mg of lactose) daily for 3 weeks for 2 w

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Satisfaction to participate in the study Aged 18-70 years Real Time PCR or CT-SCAN positive test

Exclusion criteria

Exclusion criteria: Bile problem Curcumin allergy problems Cardiovascular diseases Use of anticoagulants

Design outcomes

Primary

Measure	Time frame
Lung CT-SCAN. Timepoint: First admission and one week after admission. Method of measurement: CT-SCAN IMAGING.;Duration of hospitalization. Timepoint: Patient discharge time or death. Method of measurement: patient medical records.;Complete blood count. Timepoint: First admission and one week after admission. Method of measurement: cell counter.;C-Reactive protein. Timepoint: First admission and one week after admission. Method of measurement: Agglutination method.;LDH. Timepoint: First admission and one week after admission. Method of measurement: Spectrophotometric assay.;Erythrocyte sedimentation rate. Timepoint: First admission and one week after admission. Method of measurement: sediment analyzer.;Prothrombine time. Timepoint: First admission and one week after admission. Method of measurement: coagulometer.;Partial thromboplastine time. Timepoint: First admission and one week after admission. Method of measurement: coagulometer.;D-Dimer test. Timepoint: First admission and one week after admission. Method of measurement: nephlometery.	—

Measure

Time frame

Lung CT-SCAN. Timepoint: First admission and one week after admission. Method of measurement: CT-SCAN IMAGING.;Duration of hospitalization. Timepoint: Patient discharge time or death. Method of measurement: patient medical records.;Complete blood count. Timepoint: First admission and one week after admission. Method of measurement: cell counter.;C-Reactive protein. Timepoint: First admission and one week after admission. Method of measurement: Agglutination method.;LDH. Timepoint: First admission and one week after admission. Method of measurement: Spectrophotometric assay.;Erythrocyte sedimentation rate. Timepoint: First admission and one week after admission. Method of measurement: sediment analyzer.;Prothrombine time. Timepoint: First admission and one week after admission. Method of measurement: coagulometer.;Partial thromboplastine time. Timepoint: First admission and one week after admission. Method of measurement: coagulometer.;D-Dimer test. Timepoint: First admission and one week after admission. Method of measurement: nephlometery.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Teremmahi Ardestani

Bandare-abbas University of Medical Sciences

majidardestani50@gmail.com+98 76 3366 6367

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026